0.545, when their ShareBuyBack taking action?

Hovid has >300 products exports to >40 countries in the world.
Below are the list of products Hovid exporting
http://www.hovid.com/Content/files/Product%20Brochure%20for%20export.pdf

http://www.hovid.com/t/Product-eCatelog

http://tefd.theedgemarkets.com/2014/FDsetia/FDsetia_20141204_4bax6h.pdf
read today's the edge, VT cries and complaints that it's NOT FAIR to his MOLG.... his judgement day?

back to 0.150 level... going to 16-17 if asiabio wants to push up

makan 0.20.... yahooo!

siapa makan 0.140 tadi... terimakasihnya...

http://www.extremetech.com/extreme/194938-jackie-chan-blu-ray-disc-boosts-solar-panel-efficiency-by-a-massive-22

Mana Dracular?

waiting more discounts

bought some hundreds lots at 0.145, Solar Power.... no need oil/gas...

then later it went up few cents to 1.02

I look at the monitor and want to hit BUY when 0.98,0.99.... still not dare yet

slowly going up again

headache... today not a good buy yet lol...

rain on others - means what?
泼冷水？

bye chy72, pls lah don't come back again... you ni always gone case one...

tak semestinya...

asiabio 0.155 engine starts.... let's see

dividend banked in, yahoo....

1.47, good buy

nice summary from the klse.my website, thanks logitrader for sharing this.

CIMB ke, RHB ke, KENANGA ke... semua itu majority only for reference and for public.
For us, we need to do homework and study the company financial, business, roadmap, etc....

http://my-macdscan.blogspot.com/2014/11/scan-25-nov-14.html

http://my-movingaveragescan.blogspot.com/2014/11/scan-25-nov-14.html
Symbol Type Date Close Price Volume
HOVID BHD Bullish 11/25/2014 0.375 291600


http://my-movingaveragescan.blogspot.com/2014/11/scan-24-nov-14.html
Symbol Type Date Closing Price Volume 20 day MA 50 day MA 200 day MA
HOVID BHD Long term bullish 11/24/2014 0.375 311800 0.38 0.384 0.373

HOVID (7213) : Hovid Bhd - Decent start to FY15

Target RM0.41 (Stock Rating: HOLD)

Hovid’s 1QFY6/15 core net profit was broadly in line, making up 27% of our and consensus full-year forecasts. Its sales and profit margin improved marginally due to higher selling prices and a favourable foreign exchange rate. As expected, no dividend was declared. We trim our FY15-17 EPS by 1-2% after updating our financial model with the latest numbers from its annual report. We keep our SOP-based target price at RM0.41, but upgrade it to Hold from Reduce as its share price has corrected by 18% since we downgraded it to Reduce in Aug 14. We prefer Pharmaniaga for its higher upside.

Key results highlights
Hovid’s 1Q15 net profit rose by 26% yoy to RM5.8m, lifted by higher sales. However, EBITDA margin recorded a marginal drop of 0.4% pts from the level a year ago to 19% due to higher research and development expenditure. Excluding these R&D costs, EBITDA margin would have been 0.4% pts higher than last year. We believe the price revision exercise completed in 2HFY14 contributed partly to the higher revenue and profit margin. The weaker RM has also boosted its earnings. Hovid booked a foreign exchange gain of RM0.9m in 1Q15, higher than the RM0.3m gain recognised in 1Q14.

Capacity constraint could limit sales growth
Despite the stronger yoy quarterly performance, its revenue grew by only 2% qoq while EBITDA margin improved by only 0.1% pts. During our Healthcare Corporate Day last month, Hovid revealed that its sales growth is still constrained by its plants’ capacity, which is almost fully utilised. We gathered that its order backlog has risen to RM35m (from RM30m two months ago). Capacity constraint is likely to limit its revenue growth in the near term, as its new tablet and capsule plant will only begin operations around Jul-Aug next year.

We upgrade to Hold
Hovid’s share price has fallen by 18% and underperformed the broader market by 16% since we downgraded it to Reduce in Aug 14. We are upgrading our recommendation to Hold as its valuations are now more reflective of its earnings growth prospects. We would turn more positive on the stock if its sales or profit margin substantially exceed our expectation.

Source: CIMB Daybreak - 26 November 2014

HOVID (7213) : CIMB Research upgrades Hovid to Hold, target price 41 sen
KUALA LUMPUR (Nov 26): CIMB Research has upgraded Hovid Bhd to Hodl (from Reduce) at 38 sen with an unchanged target price of 41 sen and said Hovid’s 1QFY6/15 core net profit was broadly in line, making up 27% of house and consensus full-year forecasts.

In a note Nov 25, the research house said Hovid’s sales and profit margin improved marginally due to higher selling prices and a favourable foreign exchange rate.

It said that as expected, no dividend was declared.

“We trim our FY15-17 EPS by 1-2% after updating our financial model with the latest numbers from its annual report.

“We keep our SOP-based target price at 41 sen, but upgrade it to Hold from Reduce as its share price has corrected by 18% since we downgraded it to Reduce in Aug 14.

“We prefer Pharmaniaga for its higher upside,” it said.

http://www.theedgemarkets.com

top-up to add some more, keep it it safefy box.

Anyone attended agm today? Mind to share if any special news?

i buy 1 lot 1 lot too but today it's not me

bye chy72, quickly sell 300 lots, and don't come back lah, you not belongs here.

0.780,0.785...aiya....misssed

bye chy72, if you have sold all with some earning, congrats... and pls go away and don't come back

http://solarenergy.einnews.com/article_detail/234623865?lcode=jPvSGTfL5L_yjnck5oKpnFZxtyYtPrRavfGubuxxpSQ%3D

Malaysia awards over 250MW solar FiTs
Nov 14, 2014 - 12:33 GMT
The Sustainable Energy Development Authority Malaysia (SEDA Malaysia) has approved 250MW of solar projects to receive its feed-in tariff (FiT). Over 4,600 FiT applications have been approved by SEDA as of the end of October this year – totalling 917MW of renewable energy – just over 250MW of which are solar projects. Out of the solar applications, 210MW is non-residential....


VSOLAR sudah apply.... sudah dapat ke?

HongLeong IB

Pharmaniaga (BUY)
9M14 Results – In Line

9M14 core net profit of RM71.9m, came in within our expectations but slightly ahead of consensus’ estimates, accounting for 77% and 83% of HLIB and consensus full year estimates, respectively.
Declared 3rd single tier dividend of 8.0 sen per share (3Q13: 3.0 sen) with ex-date on 5th Dec.
3Q14 revenue gained 13.9% yoy to RM502.1m contributed by the entire core business operations. However, qoq sales contracted 4.4% due to seasonally lower demand.
Logistics and Distribution Division posted more than three-fold increase in PBT qoq, boosted by higher ASP coupled with higher sales volume. Manufacturing Division’s PBT slipped due to lower off-take for in-house products from government hospitals as well as higher R&D expenses.
Moving forward, Pharmaniaga remains positive as the pharmaceutical sector in Malaysia is showing improved prospects.
Reiterate BUY with unchanged fair value of RM5.30 based on FY15 P/E multiple of 14.5x, 10% discount to US peers.

HongLeong IB
ViTrox (BUY)
Deliver as Promised

Again, achieved new highs in revenue and profit merely with 9 months results. FY14 top line is forecasted grow 55.7% yoy reaching ~RM165m.
MVS-S: resilient 3Q14 order despite seasonality weakness. 4Q14 revenue is forecasted to be ranging RM9-10m. Demand is expected to pick up from 2Q15 onwards.
MVS-T: YTD 9M14 sales more than doubled (+173.7%) yoy and 4Q14 sales expected to be between RM6-8m.
ABI: 3Q14 fell dragged by disappointment in PCB. 4Q14 revenue forecast is estimated to be RM20m while carry forward backlog into 1Q15 will be higher than in 2H14.
By summing the mid-points of those guidance, 4Q14 sales could potentially grow 30.4% yoy to RM36.5m.
Confident to extend its pioneer status / tax exemptions which will end in 1Q15.
Reiterate BUY with unchanged TP of RM3.17, pegged to 1SD above 5-year historical average P/E multiple of 16.2x.

To who promotes BJCORP.... VT.... read it yourself for his newly listed company in US (MOLG)
Share price plunged down >50% (on last Friday, yeah, dropped 53.84% on that day itself)

VT's MOLG just listed on Nasdaq and last Friday disaster!
MOL Global, Inc. Stock Chart [MOLG]
$4.09 (-4.77) down 53.84% [in a day]
-data as of Nov. 21, 2014 (read more from http://www.nasdaq.com/symbol/molg)

http://www.themalaymailonline.com/money/article/mol-on-nasdaq-this-is-just-the-beginning

http://www.intellecpoint.com/2014/11/hiccup-for-mol-global.html

ALSO... some other disasters in happening,
1) CFO resigned
2) rescheduled it's third quarter financial result....

SHAREHOLDER ALERT: Investigation on Behalf of Investors of MOL Global, Inc. Announced by Law Offices of Howard G. Smith

http://www.businesswire.com/news/home/20141121005969/en/SHAREHOLDER-ALERT-Investigation-Behalf-Investors-MOL-Global#.VHIDvPmSyRF

... the Company has rescheduled the date it plans to release its third quarter 2014 financial results to December 3, 2014, before the market opens. In addition, MOL Global announced that the Group Chief Financial Officer of the Company, who joined MOL Global in August 2014, has tendered his resignation, effective immediately, “due to personal reasons.”

All are waiting to see the next coming report (next week out), also Asiabio keep buying this shares, so perhaps some gambling into this counter.

Anyway, hold until this qtr report and some news (hopefully) from Asiabio.
If ignore these 2 reasons, VSOLAR gets 21-years TNB contract, and it sure continue to grab more contracts and new business, thus good to hold for at least next 6-12 months.

actually curious, who sell that huge shares??

99.9%??? my screen shows 100%

no announcement for yesterday date 20 Nov yet, not sure who eaten, by default we know "MARA"

simon84, salute you all, with this strategy, sure win (YOU ALL).

ikan jerung datang and pergi, habis semua ikan kecil-kecil/masin ni, kekeke....

rest time, when 2:30pm open, 0.150 sure all eaten up and moving to 0.155 level... incredible shark!

hits 365 continuously BUYING transactions...and still non-stop...with avg 666 lots/each buy transaction... cool man

WOW... POWERFUL...!
not retailers style at all, who buy?

asiabio 0.145 buyers come, later vsolar's turn? hehehe....

0.145 buyers coming... show started

naik naik naik... Calvin hilang lenyap
turun turun turn... Calvin timbul buat-kacau hari hari

shila, I love you....

0.170, good buy